Join our Mailing List Press Release
Osmetech plc ('Osmetech' or the 'Company')
RESULTS OF EXTRAORDINARY GENERAL MEETING
1 October 2008
The Company is pleased to announce that, further to its announcement on 12 September 2008, the resolution to approve the issue of up to 221,375,000 new ordinary shares and the amendments to the Company's 2003 US Equity Compensation Plan was successfully passed by shareholders at the Company's Extraordinary General Meeting held today. As described in the announcement of 12 September, the Company is proposing to offer American Depositary Shares ("ADSs") and new ordinary shares of 0.10p each, and to seek a listing of its ADSs on the NASDAQ Global Market ("Offering").
A further announcement will be made when the issue price and the actual number of ADSs and new ordinary shares proposed to be issued pursuant to the Offering has been determined.
Enquiries:
Osmetech plc +44 (0)207 849 6027
James White, Chief Executive Officer
David Sandilands, Chief Financial Officer
Madano Partnership +44 (0) 207 593 4000
Matthew Moth, Mark Way
Canacccord Adams Limited +44 (0) 207 050 6500
Robert Finlay
L. Warren Pimm
Lazard Capital Markets LLC
David McMillan +1 212 632 6719
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy new Ordinary Shares or ADSs or any other security in the United States or in any such jurisdiction in which any such offer, solicitation or sale would be unlawful. New Ordinary Shares or ADSs or other securities may not be offered or sold in the United States absent registration or an exemption from registration. The public offering of such securities to be made in the United States is being made by means of a prospectus that forms a part of a registration statement filed by the Company with the US Securities and Exchange Commission and no sales of such securities shall be made nor offers to buy be accepted until such registration statement is declared effective. A copy of the offering document may be obtained from the Company which contains detailed information about the Company and its management, as well as the Company's most recent audited financial statements.
About Osmetech plc
(www.osmetech.com)
Osmetech plc is a fast developing, international diagnostics business with operations in Boston and Pasadena in the US, serving the high growth molecular diagnostic market targeting hospitals and reference laboratories. Osmetech has rights to a strong portfolio of over 200 issued and pending patents and has launched its first generation eSensor 4800 platform, an electrochemistry-based array system, together with an FDA cleared in vitro diagnostic test for Cystic Fibrosis carrier detection. In July 2008, Osmetech received FDA clearance for its second generation eSensor XT-8 molecular diagnostics platform and Warfarin Sensitivity Test.